Fig. 1 · Structure

Documents & Downloads

Sitafloxacin

Cat. No. A10847 CAS 127254-12-0
Sitafloxacin is a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections. Sitafloxacin is active against methicillin-resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced susceptibility to levofloxacin and other quinolones and enterococci.

In Stock

Publications for Sitafloxacin

1 publication citing this product

  1. Seyedeh Bita Mousavinafchi, .et al. , Food Sci Nutr, 2022, Nov 21;11(2):1142-1153 PMID: 36789060

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Sitafloxacin inhibited purified bacterial DNA gyrase and topoisomerase IV in electrophoretic activity assays. For the reported sesquihydrate, IC50 values were 0.13 ± 0.01 μg/ml for E. coli DNA gyrase and 0.39 ± 0.15 μg/ml for S. aureus topoisomerase IV (± SD). These measurements use enzymes from different species. [1]

In the same paper, the reported IC50 for human placenta topoisomerase II was 2,369 ± 101 μg/ml (± SD). The weaker inhibition in this enzyme counter-assay supports assay-specific selectivity; it does not establish cellular or in vivo safety. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Quinolone  

Sitafloxacin Research Summary

This section summarizes 2 in vitro studies of Sitafloxacin from 1 published reference. In vitro models include commercial human placenta topoisomerase II.

Sitafloxacin In Vitro Studies

Inhibition of bacterial type II topoisomerases

Biochemical assay · Purified E. coli KL-16 DNA gyrase and S. aureus FDA 209-P topoisomerase IV. [1]

Electrophoretic enzyme assays compared sitafloxacin with three stereoisomers and levofloxacin, ofloxacin and ciprofloxacin. Sitafloxacin had the lowest IC50 against each bacterial enzyme in this panel.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of DNA gyrase supercoilingIC50 0.13 ± 0.01 μg/ml (IC50 ± SD)[1]
Inhibition of topoisomerase IV decatenationIC50 0.39 ± 0.15 μg/ml (IC50 ± SD)[1]

Literature-Reported Treatment Conditions

Exposure duration
DNA gyrase reaction: 1 h; topoisomerase IV reaction duration not stated in the retrieved paragraph.
Method
Electrophoretic enzyme-activity assays; DNA gyrase reaction at 37°C.
Reported limits
IC50 values are assay endpoints, not treatment concentrations. Replicate number and drug solvent are not stated in the selected enzyme-method text.
Methods and source locations

Compound reported in the paper: Sitafloxacin; Compound label in the paper: DU-6859a

Evidence concerns the reported sesquihydrate. Values remain in reported mass units; no conversion to the catalog anhydrous formula or Adooq lot validation.

Table 2; enzyme-source and electrophoretic enzyme-assay paragraphs; Introduction and Figure 1

Inhibition of DNA gyrase supercoiling: Gel-based quantification of supercoiled plasmid DNA. — Table 2, Sitafloxacin row and footnote; electrophoretic enzyme-assay paragraph

Inhibition of topoisomerase IV decatenation: Concentration reducing decatenation by 50% relative to drug-free controls. — Table 2, Sitafloxacin row and footnote; electrophoretic enzyme-assay paragraph

Human topoisomerase II counter-assay

Biochemical assay · Commercial human placenta topoisomerase II. [1]

The human enzyme relaxation assay required a substantially higher sitafloxacin concentration for 50% inhibition than the bacterial assays. This biochemical comparison does not establish cellular or organismal safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of human topoisomerase II relaxationIC50 2,369 ± 101 μg/ml (IC50 ± SD)[1]

Literature-Reported Treatment Conditions

Exposure duration
1 h
Method
Plasmid relaxation assay at 37°C.
Reported limits
Replicate number and drug solvent are not specified in the selected assay text. Reported IC50 is not a cellular treatment dose.
Methods and source locations

Compound reported in the paper: Sitafloxacin; Compound label in the paper: DU-6859a

Evidence concerns the reported sesquihydrate. Values remain in reported mass units; no conversion to the catalog anhydrous formula or Adooq lot validation.

Table 2, human Topo II column and footnote; enzyme-source and relaxation-assay paragraph; discussion of mammalian enzyme selectivity

Inhibition of human topoisomerase II relaxation: Electrophoretic quantification of plasmid relaxation; IC50 calculated by the same approach as the DNA gyrase assay. — Table 2, Sitafloxacin row and footnote; electrophoretic enzyme-assay paragraph

Specifications

Manufacturer Adooq Bioscience
CAS Number 127254-12-0
Formula C19H18ClF2N3O3
Molecular Weight 409.8178
Synonyms DU 6859; DU 6859A
SMILES
O=C(C1=CN([C@H]2[C@@H](F)C2)C3=C(C=C(F)C(N(C[C@H]4N)CC54CC5)=C3Cl)C1=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 4 mg/mL (9.15 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Sitafloxacin Research References

  1. [1] Takaaki Akasaka, Seiko Kurosaka, Yoko Uchida, et al. Antibacterial Activities and Inhibitory Effects of Sitafloxacin (DU-6859a) and Its Optical Isomers against Type II Topoisomerases Antimicrobial Agents and Chemotherapy (1998). PMID: 9593169 DOI: 10.1128/aac.42.5.1284 Source material

Publications

1 publication citing this product

  1. Seyedeh Bita Mousavinafchi, .et al. , Food Sci Nutr, 2022, Nov 21;11(2):1142-1153 PMID: 36789060

Added to your cart

View Cart Checkout
Loading...